Press Releases

September 27, 2021
Venatorx Pharmaceuticals, along with its collaborators, will present seven posters and two oral abstracts at IDWeek 2021, which is taking place virtually September 29 – October 3, 2021.
August 17, 2021
Venatorx Pharmaceuticals announced a comprehensive update about cefepime-taniborbactam, the Company’s intravenous beta-lactam / beta-lactamase inhibitor combination antibiotic that is being developed for the treatment of cUTIs and HABP/VABP.
July 28, 2021
VNRX-7145, in combination with ceftibuten, is designed for the treatment of patients with infections caused by multi-drug resistant (MDR) gram-negative pathogens that are resistant to current standard-of-care oral and intravenous antibiotics, including fluoroquinolones, cephalosporins and carbapenems.

In the News

August 31, 2021
GARDP REVIVE
GARDP was able to make progress in 2020 despite the challenges of the COVID-19 pandemic. This webinar highlighted efforts to advance antibiotic R&D in the midst of the pandemic and underscored the importance of investing in the development of new and improved treatments for drug-resistant infections that pose the greatest threat to health.
August 05, 2021
Philadelphia Business Journal
Several Philadelphia-area life sciences companies made significant progress this week with development of new drug candidates targeting heart disease and viral and bacterial pathogens including Covid-19. Here's a rundown.

Social Media

Upcoming Events

Monday, November 08, 2021 - Tuesday, November 09, 2021
Saturday, April 23, 2022 - Wednesday, April 26, 2023
Thursday, June 09, 2022 - Monday, June 13, 2022